Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Passage Bio, Inc. Common Stock

PASG

Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $3.59 – $4.13
Volume 7,056
Market cap $13M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$13.29M
Price / earnings
—
Price / book
265.79×
Price / sales
—
EV / sales
—
EV / EBITDA
0.2×

Profitability

Earnings per share
-$10.28
Return on assets
-159.1%
Return on equity
-66,164%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
1×
Quick ratio
1×
Cash ratio
0.97×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$32.65M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PASG, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$3.44M$6.87M$4.79M$4.92M$4.35M$4.52M$6.09M$4.71M
Research and development$1.5M$3.34M$4.09M$5.42M$4.31M$5.81M$7.74M$9.56M
Total operating expenses$4.94M$8.27M$8.88M$13.85M$8.66M$10.33M$16.46M$14.27M
Operating income-$4.94M-$8.27M-$8.88M-$13.85M-$8.66M-$10.33M-$16.46M-$14.27M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$4.72M-$7.82M-$7.56M-$12.98M-$7.75M-$9.39M-$15.41M-$12.73M
Income taxes$0$0$0$0$0$0$0$0
Net income-$4.72M-$7.82M-$7.56M-$12.98M-$7.75M-$9.39M-$15.41M-$12.73M
Net income attributable to common shareholders-$4.72M-$7.82M-$7.56M-$12.98M-$7.75M-$9.39M-$15.41M-$12.73M
EBITDA-$4.94M-$10.19M-$8.75M-$10.16M-$8.47M-$10.17M-$13.62M-$13.55M
Basic earnings per share-$1.47-$2.44-$2.36-$4.08-$2.44-$2.96-$4.87-$3.96
Diluted earnings per share-$1.47-$2.44-$2.36-$4.08-$2.44-$2.96-$4.87-$3.96

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Investigation for the Merger — BWMN, UTZ , PASG and FNWD

Class action law firm Monteverde & Associates PC is investigating four proposed mergers to determine if shareholders are receiving fair deal terms. The investigations cover Bowman Consulting Group's sale to Bernhard Capital Partners ($43.00/share), Utz Brands' sale to Intersnack Group ($14.25/share with vote on Nov 13), Passage Bio's merger with Remix Therapeutics (vote on Nov 5), and Finward Bancorp's sale to First Financial Bancorp (1.35 share exchange ratio with vote on Nov 2).

GlobeNewswire Inc.

$HAREHOLDER ALERT: IS IT A FAIR DEAL FOR YOU? The M&A Class Action Firm Is Investigating the Merger — UTZ, SAFT, PASG and FNWD

Class action law firm Monteverde & Associates PC is investigating four major merger and acquisition transactions to determine if shareholders are receiving fair deal terms. The investigations involve Utz Brands' sale to Intersnack Group, Safety Insurance Group's sale to Mapfre affiliate, Passage Bio's merger with Remix Therapeutics, and Finward Bancorp's sale to First Financial Bancorp.

GlobeNewswire Inc.

Sandhoff Disease Treatment Market Size Projects USD 456.42 Million by 2034

The global Sandhoff disease treatment market is projected to grow from $260 million in 2024 to $456.42 million by 2034, with a 5.75% CAGR. North America dominates the market, and gene therapy is expected to be a key growth segment for treating this rare genetic disorder.

GlobeNewswire Inc.

2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies

The report provides a comprehensive analysis of the Adeno-Associated Virus (AAV) Vectors in Gene Therapy pipeline, highlighting the potential of this technology to revolutionize the treatment of genetic disorders. It examines the challenges in scalable production and safety, as well as the industry's focus on optimizing vectors for improved safety, specificity, and efficiency.

GlobeNewswire Inc.

Passage Bio to Participate in Upcoming Investor Conferences

Passage Bio, a clinical-stage genetic medicines company, announced that it will participate in upcoming investor conferences, including the TD Cowen 45th Annual Health Care Conference and the Leerink Global Biopharma Conference.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jul 14, 20251-for-20reverse split
Jun 1, 200420-for-1forward split